Evidence map›Paper›PMID 31963368›Full record

ReviewJournal of clinical medicine2020

Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy.

Ruxandra I Sava, Carl J Pepine, Keith L March

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Interferon gamma signaling drives cardiac metabolic rewiring.bioRxiv : the preprint server for biology · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. The Gut Microbiome of Heart Failure With Preserved Ejection Fraction.Journal of the American Heart Association · 2021
    Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Ruxandra I SavaCenter for Regenerative Medicine, University of Florida, Gainesville, FL 32610, USA.
Carl J PepineDivision of Cardiovascular Medicine, Department of Medicine, University of Florida, Gainesville, FL 32610, USA.
Keith L MarchCenter for Regenerative Medicine, University of Florida, Gainesville, FL 32610, USA.
University of Florida · USClinical Emergency Hospital Bucharest · RO

Funding

Using social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2M
Data Coordinating Center For The Cardiovascular Cell Therapy Research NetworkUM1HL087318 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DAVIS, BARRY R · 2012 to 2018
$29.8M
UFRCC for Cardiovascular Cell Therapy Research NetworkUM1HL087366 · NHLBI · UNIVERSITY OF FLORIDA · PI PEPINE, CARL J · 2012 to 2018
$4.7M
Brain-Gut Microbiome-Immune Axis in HypertensionR01HL132448 · NHLBI · UNIVERSITY OF FLORIDA · PI Carl J Pepine, Steven Michael Smith · 2016 to 2026
$4.5M
National Institutes of Health, National Center for Advancing Translational Sciences-University of Florida Clinical and Translational Science UL1TR001427NHLBI: Brain-Gut Microbiome-Immune Axis in Hypertension HL132448NHLBI NIH HHS UM1 HL087318NHLBI NIH HHS UM1 HL087366PCORnet - One Florida Clinical Research Consortium, Clinical Data Research Network-1501 26692The Gatorade Trust 00128251The Gatorade Trust: 00128225The Romanian-American Fulbright Commission N/A
6 · The paper itself

Abstract

Over 26 million people worldwide suffer from heart failure, a disease associated with a 1 year mortality rate of 22%. Half of these patients present heart failure with preserved ejection fraction (HFpEF), for which there is no available therapy to improve prognosis. HFpEF is strongly associated with aging, inflammation, and comorbid burden, which are thought to play causal roles in disease development. Mesenchymal stromal/stem cells (MSCs) have potent immunomodulatory actions and promote tissue healing, thus representing an attractive therapeutic option in HFpEF. In this review, we summarize recent data suggesting that a two-hit model of immune dysregulation lies at the heart of the HFpEF. A first hit is represented by genetic mutations associated with clonal hematopoiesis of indeterminate potential (CHIP), which skew immune cells toward a pro-inflammatory phenotype, are associated with HFpEF development in animal models, and with immune dysregulation and risk of HF hospitalization in patients. A second hit is induced by cardiovascular risk factors, which cause subclinical cardiac dysfunction and production of danger signals. In mice, these attract proinflammatory macrophages, Th1 and Th17 cells into the myocardium, where they are required for the development of HFpEF. MSCs have been shown to reduce the pro-inflammatory activity of immune cell types involved in murine HFpEF in vitro, and to reduce myocardial fibrosis and improve diastolic function in vivo

Indexed as

CHIPHFpEFimmune dysregulationinflammationmesenchymal stromal/stem cellsMSC

Identifiers

PMID31963368
PMCPMC7019215
OpenAlexW2999392114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.